Table 5.
First 15 functional groups (lower adjusted p-value) of biological processes enriched for cluster of colosEV miRNA targets. For Clusters 11, 12 and 15, no statistically significant enriched terms were found.
| colosEV miRNA targets | Function | Group adjusted p-value | no. of terms | Groups |
|---|---|---|---|---|
|
Cluster1 SNW1 |
RNA processing | 1.0E−41 | 9 | Group50 |
| Positive regulation of chromosome organization | 5.8E−26 | 56 | Group67 | |
| DNA repair | 4.8E−21 | 18 | Group61 | |
| Positive regulation of telomere maintenance | 2.0E−19 | 40 | Group65 | |
| Positive regulation of DNA metabolic process | 7.8E−19 | 35 | Group64 | |
| Regulation of DNA metabolic process | 2.1E−18 | 10 | Group53 | |
| Regulation of chromosome organization | 1.2E−17 | 53 | Group66 | |
| DNA metabolic process | 1.2E−14 | 5 | Group35 | |
| Spliceosomal complex assembly | 2.8E−14 | 3 | Group27 | |
| Cytoplasmic translation | 1.2E−11 | 11 | Group55 | |
| Negative regulation of gene expression | 3.0E−10 | 13 | Group57 | |
| Cell cycle checkpoint signaling | 1.8E−09 | 13 | Group58 | |
| Regulation of RNA splicing | 1.6E−08 | 8 | Group46 | |
| Mitotic sister chromatid segregation | 2.1E−08 | 14 | Group59 | |
| Chromatin organization | 2.1E−08 | 33 | Group63 | |
|
Cluster2 MED4-SUR2-ARC70-ARC34-MED12-ARG1-ARC77-ARC205-MED30 |
Transcription initiation from RNA polymerase II promoter | 2.6E−35 | 4 | Group23 |
| Positive regulation of transcription initiation from RNA polymerase II promoter | 3.5E−17 | 16 | Group36 | |
| Centrosome cycle | 1.6E−12 | 27 | Group38 | |
| Histone acetyltransferase activity | 6.1E−11 | 6 | Group30 | |
| Microtubule cytoskeleton organization | 2.0E−09 | 12 | Group32 | |
| DNA-directed 5'-3' RNA polymerase activity | 2.7E−08 | 2 | Group17 | |
| RNA polymerase II general transcription initiation factor activity | 5.1E−08 | 19 | Group37 | |
| Histone H3 acetylation | 9.8E−08 | 5 | Group28 | |
| Peptidyl-lysine modification | 1.0E−07 | 3 | Group19 | |
| Intraciliary transport involved in cilium assembly | 5.0E−07 | 13 | Group35 | |
| Regulation of RNA splicing | 4.6E−06 | 3 | Group20 | |
| Nuclear receptor coactivator activity | 5.3E−05 | 1 | Group04 | |
| Signal transduction in response to DNA damage | 1.5E−04 | 13 | Group34 | |
| Nuclear mRNA surveillance | 2.3E−04 | 13 | Group33 | |
| Intraciliary transport | 2.3E−04 | 5 | Group27 | |
|
Cluster3 GYS1-KANK2 |
Glycogen catabolic process | 0.0E + 00 | 1 | Group01 |
| Spinal cord motor neuron differentiation | 0.0E + 00 | 1 | Group03 | |
| Vitamin D receptor signaling pathway | 0.0E + 00 | 1 | Group05 | |
| Centriole replication | 0.0E + 00 | 2 | Group08 | |
| Glycogen metabolic process | 0.0E + 00 | 3 | Group11 | |
| Regulation of extrinsic apoptotic signaling pathway | 0.0E + 00 | 3 | Group12 | |
| Cellular response to nitrogen starvation | 0.0E + 00 | 5 | Group13 | |
| Negative regulation of G1/S transition of mitotic cell cycle | 1.0E−02 | 1 | Group07 | |
| Positive regulation of cell-substrate adhesion | 1.0E−02 | 2 | Group09 | |
| Regulation of glycoprotein biosynthetic process | 2.0E−02 | 1 | Group00 | |
| Intermediate filament cytoskeleton organization | 2.0E−02 | 1 | Group04 | |
| Negative regulation of cell migration involved in sprouting angiogenesis | 2.0E−02 | 2 | Group10 | |
| Reciprocal meiotic recombination | 3.0E−02 | 1 | Group02 | |
| Protein localization to microtubule cytoskeleton | 3.0E−02 | 1 | Group06 | |
|
Cluster4 PEAK1 |
Protein tyrosine kinase activity | 4.4E−09 | 6 | Group10 |
| Late endosome to lysosome transport | 6.6E−06 | 16 | Group11 | |
| RNA polymerase II general transcription initiation factor activity | 5.1E−05 | 4 | Group09 | |
| Positive regulation of protein localization to membrane | 6.2E−04 | 2 | Group08 | |
| Hippocampus development | 6.3E−04 | 1 | Group01 | |
| Regulation of potassium ion transmembrane transport | 6.8E−04 | 2 | Group06 | |
| Regulation of early endosome to late endosome transport | 7.5E−04 | 1 | Group02 | |
| Glutamate secretion | 9.3E−04 | 1 | Group00 | |
| Regulation of long-term neuronal synaptic plasticity | 9.3E−04 | 1 | Group03 | |
| axo-dendritic transport | 2.5E−03 | 2 | Group05 | |
| Cellular response to amyloid-beta | 2.8E−03 | 1 | Group04 | |
| Regulation of amyloid-beta formation | 3.8E−03 | 2 | Group07 | |
|
Cluster5 USP9-KIAA0928 |
Negative regulation of cellular amide metabolic process | 3.9E−16 | 29 | Group19 |
| Regulation of translation | 2.0E−15 | 10 | Group18 | |
| Negative regulation of cellular macromolecule biosynthetic process | 4.6E−15 | 7 | Group15 | |
| Regulation of mRNA stability | 6.1E−15 | 6 | Group13 | |
| Regulation of mRNA metabolic process | 4.4E−14 | 6 | Group12 | |
| mRNA destabilization | 8.0E−14 | 8 | Group16 | |
| RIG-I signaling pathway | 9.8E−10 | 20 | Group17 | |
| RNA transport | 6.5E−09 | 6 | Group14 | |
| Peptidyl-serine phosphorylation | 7.6E−09 | 1 | Group05 | |
| Protein tyrosine kinase activity | 1.5E−07 | 3 | Group07 | |
| Regulation of cytokine-mediated signaling pathway | 5.7E−07 | 4 | Group10 | |
| Regulation of type I interferon-mediated signaling pathway | 5.1E−05 | 5 | Group11 | |
| Negative regulation of glycoprotein biosynthetic process | 1.6E−04 | 1 | Group04 | |
| JUN kinase kinase kinase activity | 1.8E−04 | 3 | Group09 | |
| Regulation of NIK/NF-kappaB signaling | 2.9E−04 | 1 | Group02 | |
|
Cluster6 TIF1A-MLL3 |
DNA-binding transcription activator activity. RNA polymerase II-specific | 3.0E−20 | 1 | Group00 |
| Chromatin organization | 1.7E−12 | 1 | Group04 | |
| Mesenchymal cell apoptotic process involved in metanephros development | 8.4E−12 | 37 | Group14 | |
| Gastrulation | 8.7E−10 | 13 | Group13 | |
| Peptidyl-lysine modification | 9.6E−10 | 3 | Group09 | |
| Regulation of kidney size | 4.2E−08 | 13 | Group12 | |
| miRNA transcription | 2.0E−06 | 3 | Group08 | |
| Camera-type eye morphogenesis | 6.5E−06 | 4 | Group11 | |
| DNA methylation-dependent heterochromatin assembly | 1.2E−04 | 4 | Group10 | |
| Cellular response to dopamine | 1.4E−03 | 1 | Group02 | |
| Histone lysine demethylation | 2.0E−03 | 1 | Group01 | |
| Protein sumoylation | 2.3E−03 | 1 | Group06 | |
| Regulation of peptidyl-lysine acetylation | 5.2E−03 | 1 | Group03 | |
| Centriole replication | 5.3E−03 | 1 | Group05 | |
| Macrophage chemotaxis | 6.7E−03 | 1 | Group07 | |
|
Cluster7 SP1 |
miRNA transcription | 7.0E−06 | 4 | Group5 |
| Negative regulation of protein modification by small protein conjugation or removal | 2.8E−04 | 1 | Group1 | |
| Fc-gamma receptor signaling pathway involved in phagocytosis | 4.9E−04 | 1 | Group3 | |
| Regulation of cyclin-dependent protein serine/threonine kinase activity | 5.0E−04 | 1 | Group0 | |
| Regulation of gene silencing by RNA | 5.7E−04 | 3 | Group4 | |
| Endodermal cell differentiation | 1.9E−03 | 1 | Group2 | |
|
Cluster8 RXRA |
Nuclear receptor activity | 3.6E−07 | 1 | Group0 |
| Regulation of myeloid cell differentiation | 4.5E−07 | 7 | Group5 | |
| Cellular response to nutrient | 1.6E−06 | 2 | Group4 | |
| Regulation of blood vessel endothelial cell migration | 4.5E−05 | 1 | Group1 | |
| Positive regulation of keratinocyte differentiation | 5.4E−05 | 1 | Group2 | |
| Regulation of microvillus assembly | 8.2E−05 | 2 | Group3 | |
|
Cluster9 CHD2 |
Maintenance of postsynaptic specialization structure | 1.6E−05 | 2 | Group3 |
| Intermediate filament cytoskeleton organization | 2.7E−04 | 1 | Group0 | |
| Dendritic spine development | 3.1E−04 | 1 | Group2 | |
| Regulation of focal adhesion assembly | 6.4E−03 | 1 | Group1 | |
|
Cluster10 BCLAF3 |
Acetyl-CoA biosynthetic process from pyruvate | 0.0E + 00 | 1 | Group0 |
| Centriole replication | 0.0E + 00 | 1 | Group1 | |
| mRNA export from nucleus | 0.0E + 00 | 10 | Group2 | |
|
Cluster13 RXRB |
Nuclear receptor activity | 6.2E−10 | 1 | Group0 |